Lipoprotein lipase (EC 3.1.1.34), as the extrahepatic enzyme responsible for the hydrolysis of plasma lipoprotein triacylglycerol, plays a pivotal role in the metabolism of circulating lipids. The Occurrence and action of the enzyme in lipoprotein metabolism has been the subject of a number of recent reviews (Cryer, 1981 ; Quinn et al., 1982; Hamash & Hamash, 1983) and this aspect will not be considered here. Rather, the molecular interactions that occur in the exercise of the function of the enzyme will be considered, particularly as these are reflected by studies in uitro.
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From studies of lipoprotein lipase action in vitro it is clear that the enzyme may interact with a number of different molecular species and that the relationships which exist between these various binding events contribute to the control of functional activity. Taking the: events separately, the first is associated with the catalytic or active site of the enzyme.
The active site of lipoprotein lipase is relatively nonspecific in that it hydrolyses tri-, di-and mono-acylglycerols as well as phospholipids. However, the positional specificity of hydrolysis is strict for all substrates with a preferential cleavage of the sn-1(3) ester bonds with subsequent isomerization of the 2-monoacylglyce:rol for complete breakdown (Scow & Olivecrona, 1977) The enzyme will also hydrolyse water-soluble model substrates, e.g. p-nitrophenyl-butyrate. A study of the effects of pH on the kinetic parameters exhibited by the enzyme in s'olution suggest the involvement of the imidazole side chain of histidine in the catalytic mechanism. However, corroboration by covalent modification of the active site and the isolation of a labelled histidine is awaited. Although little direct evidence exists for the involvement of an active-site sei-ine residue in the action of the enzyme, various inhibitors cf serine proteinase and serine esterase activity can also inhibit lipoprotein lipase under appropriate conditions (e.g. di-isopropylfluorophosphate, phenylmethanesulphonyl fluoride, diethyl-pnitrophenylphosphate). Quinn et ul. (1982) have indicated that a 'serine esterase-like' mechanism appears best able to accommodate observations from both t t e pH rate and the covalent modification experiments on lipoprotein lipase.
The catalytic efficiency of the enzyme is high, and with long-chain acylglycerols as substrate each lipoprotein lipase can hydrolyse 1000 ester bondsis. In order to accommodate the observed rate at which, for example, a chylomicron of 0 . 1 6~~ diameter containing 1.3 x lob triacylglycerol molecules is degraded, a number of enzyme molecules must act together on each lipoprotein particle. It can be shown that, in general, the rate of triacylglycerol hydrolysis is proportional to the number of enzyme molecules bound to each lipoprotein particle and for a chylomicron of the size indicated above, approx. 30-40 enzyme molecules would be required to act in concert to bring about the maximal rate of hydrolysis observed in ritro (see below also).
The second discernible site on the lipoprotein lipase molecule is that which may be described as the lipid (interfacial)-binding site. This site is distinct from the active site and has been proposed because of the observed ability of the enzyme to bind to lipoproteins, lipid emulsions and liposomes in the absence of the activator protein or hydrolysis. The binding through this site is reversible and accounts for the observed rapid movement of the enzyme between lipoprotein particles in vitro.
Abbreviation used: apo C-11, apolipoprotein C-11.
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A third site, distinct from those already described, on the enzyme is responsible for the interaction between lipoprotein lipase and its activator protein, apo C-11. The presence of the activator protein is obligatory for the hydrolysis of lipoproteins or triacylglycerol emulsions by the enzyme but may not be required when non-physiological water-soluble substrates are studied. It is clear that a distinct binding site is involved because, not only may the enzyme and activator form a complex in solution but the affinity between them is enhanced greatly when both are present at a lipid interface, with which either or both may interact independently. This increased affinity in the presence of lipid may reflect the fact that both concentrate at the interface or may indicate that on binding to lipid one or both of the reactants undergofes) a conformational change which may facilitate binding and subsequent catalytic activation. Certainly, it is the case that apo C-I1 undergoes a conformational change on lipid-binding, although whether the enzyme does is not clear.
The activation of the enzyme by apo C-I1 is mediated by a direct 1 : 1 protein-protein interaction in a manner which is not dependent on any increase in the binding of the enzyme to the substrate-containing surface. The mechanism of apo C-I1 action probably involves a facilitation of the interfacial formation of the enzyme triacylglycerol complex by making the orientation of enzyme and substrate more favourable for this interaction. The catalytic enhancement is probably mediated through the interaction of the C-terminal onethird of the 78-residue apo C-11, which exists as a [)-sheet region that may complement a similar region on the enzyme. The remaining part of the apo C-I1 molecule (N-terminal sequence 1-49) contains the lipid-binding domain necessary for its interaction with the lipoprotein particle. In addition to the sites described above and which are involved directly in the hydrolysis of triacylglycerol. the enzyme is also able, via a fourth distinct region, to bind to a variety of polyanions (Bengtsson et al., 1980) . Of the polyanions studied the glycosaminoglycans have been the group to receive most attention. Indeed the use of heparin covalently linked to agarose has become a widely used affinity chromatographic step in the purification of enzyme from many sources. The enzyme-heparin interaction is ionic although it is not related merely to charge density or to the presence of N-sulphate groups. The common structural feature significant to the interactions, and which is present in the three glycosaminoglycans that bind lipoprotein lipase (heparan sulphate and, dermatan sulphate) and which is absent from those that do not (chondroitin sulphate and hyaluronic acid), is the L-iduronic acid moiety. It has been suggested many times, on the basis of circumstantial evidence (reviewed by Cryer, 1981 Cryer, , 1983 , that the binding of the enzyme to the luminal surface of the endothelium is via interaction with such glycosaminoglycan polymers. The recent more direct evidence in favour of this contention is discussed below.
As far as the binding of glycosaminoglycans to the enzyme in vitro is concerned, the other functional sites on the lipoprotein lipase molecule are unaffected by the event. Thus, the active and apo C-11-binding sites are unaffected since, among other things, lipoprotein lipase bound to immobilized heparin is active catalytically and can be stimulated fully by apo C-11. Furthermore, the enzyme will bind to lipid/water interfaces, via its lipid-binding site, equally well whether heparin is present or l i d .
The final binding site discernible on the lipoprotein lipase has been characterized by its ability to interact with either detergents, like deoxycholate, or long-chain fatty acids. The binding of deoxycholate or fatty acids has, for example, BIOCHEMICAL SOCIETY TRANSACTIONS been shown to stabilize this otherwise unstable enzyme in solution. As far as enzyme function is concerned, deoxycholate or fatty acids in the absence of a suitable acceptor like serum albumin, promote the desorption of the enzyme from its interfacial interaction with lipid. These two moieties also decrease the binding of the enzyme to heparin-agarose and interfere with the interaction between lipoprotein lipase and its activator protein, apo C-11. The fatty-acid-binding site is distinct from the interfacial (lipidbinding) site and the interaction of fatty acids with the enzyme can be reversed by the addition of albumin, which appears to have a higher affinity for them than does the enzyme. These observations can be correlated with the product-induced decline in catalytic activity that is seen in uitro when any fatty-acceptor capacity becomes saturated. Whether the rate at which fatty acids are removed from the site of lipoprotein breakdown is ever a limiting factor for lipoprotein lipase action in uiuo is unknown.
Although there is a great deal of information concerned with the interdependency of the binding sites described above, the major points may be summarized briefly as follows. Firstly, lipoprotein lipase can bind simultaneously to lipid, apo C-I1 and glycosaminoglycan. Secondly all these interactions are compatible with, or stimulate, the activesite reaction. Thirdly the interaction with fatty acids interferes with the function of the other binding sites.
The potential significance of these interactions in uiuo may be addressed by first considering the molecular events at the endothelium. Firstly, the sequestration of the enzyme at this site has received attention recently (for a full review, see Cryer, 1983) , and if the aortic endothelium can be taken as typical for the purposes of study, it can be shown that lipoprotein lipase binds to this particular endothelial surface both rapidly (maximal in 10min) and in a saturable fashion. The binding observed, which is to a single class of binding sites, is readily reversed by low concentrations of added heparin (Williams et al., 1983) . With the aortic endothelium it can be shown that at saturation 1 . 2 4~ 10" moleculesof lipoprotein lipase/cm2 become bound at physiological temperature. This represents 0.5 x lo6 molecules per endothelial cell at a density of 1.2 x lo3 molecules/pm2. If the molecules of enzyme bound to the endothelium were distributed in an equally spaced and regular array, approx. one-eighth of the cell surface would be occupied by lipoprotein lipase. Indeed, it would require just such a high level of surface occupancy by enzyme to allow the necessary number of enzyme molecules to act in the required manner to bring about the degradation of each lipoprotein particle. The geometry of the interactions would also require the lipoprotein particles to undergo the sort of rapid and repeated association (hydrolysis>-dissociation-association cycles that have been predicted from other considerations (see Schaefer et al., 1978; Olivecrona & Bengtsson, 1984) . Because of the suggested role of the polyanion site on lipoprotein lipase as the means whereby enzyme becomes bound to the endothelium via the glycosaminoglycans present, several studies have attempted to investigate the direct involvement of these molecules in enzyme sequestration. Thus Williams et al. (1983) showed that aortic endothelium had available at its surface 5.4 x 10' chains of heparan sulphate plus heparinlike glycosaminoglycans/cm2. This may be compared with the lipoprotein-lipase-binding capacity and the excess of glycosaminoglycan chains to enzyme seen to be 4: 1. It may be purely coincidental, however, that most heparansulphate proteoglycans carry approx. four glycosaminoglycan chains.
Work with endothelial cells grown in culture has also implicated heparan-sulphate-like molecules in the cellsurface binding of lipoprotein lipase. Both Cheng et al. (1981) and Shimada et al. (1981) have shown rapid, specific and saturable binding to occur between the enzyme and isolated endothelial cells and showed that reversal of the binding was only induced by adding glycosaminoglycans which contained L-iduronic acid. Cheng et al. (1981) showed that the specific activity of the enzyme was unchanged upon cell binding and that pretreatment of ?he cells with platelet-derived endoglucuronidase (proteinasefree) reduced subsequent enzyme binding by up to 90%. Shimada et al. (1981) provided further evidence for the involvement of heparan sulphate in the cellular binding of enzyme by showing that both crude and highly purified heparinase from Halobacterium heparinum, but not chondroitinase ABC, caused a large decline in the interaction.
The binding of enzyme to the glycosaminoglycan chains of endothelial cell-surface proteoglycans produces a situation where the enzyme is anchored at a distance from the plasma-membrane surface of the cell (up to 40nm). The consequences of this spatial separation have been reviewed elsewhere (Cryer, 1981 (Cryer, , 1983 .
The enzyme sequestered at the endothelial cell surface has a much shorter half-life than that in the tissue parenchymal cells. Recently, using hearts from starved rats perfused in the absence of heparin in uitro, Bagby (1983) estimated that the t+ for enzyme at the endothelium was approx. 10min. The enzyme at this site had a fractional release rate constant (&) of 0.069 compared with 0.0002 and 0.003 for alkaline phosphatase and creatine kinase respectively. Thus with hearts containing in total 150 units of activity/g, 2.1 units were released per min. It is clear from other experiments (Wallinder et al., 1979) that any released enzyme would be removed from the circulation rapidly and would therefore not interfere with the delicate balance of lipoprotein metabolism which is directed by endothelialbound lipoprotein lipase.
